QED Therapeutics, a BridgeBio company, is dedicated to developing meaningful treatment options for those with achondroplasia. In August 2018, BridgeBio launched QED to focus on precision medicine for FGFR-driven diseases. In October 2019, QED announced their preclinical data supporting tolerability and activity of low-dose Infigratinib in treating achondroplasia.
QED therapeutics is researching genetic variants that cause FGFR3 overactivity can lead to skeletal conditions such as achondroplasia. We are studying whether an investigational agent (infigratinib) has the potential to improve the irregular bone growth in achondroplasia by decreasing the overactivity of the FGFR3, thereby targeting the condition at its source. Infigratinib is not currently approved for the treatment of achondroplasia by the U.S. Food and Drug Administration (FDA) or any other health authority. Infigratinib is the only oral agent under investigation for achondroplasia and is currently being studied in the PROPEL clinical program.